Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06813014 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenetics of Response to Sitagliptin (PRS)
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT06813014 is a Phase 4 study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 400 participants.
The verdict
NCT06813014, a Phase 4 study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
This is a research study to find out how different people respond to a medication called sitagliptin. Sitagliptin is an FDA approved medication that is used to treat diabetes. We are asking for healthy, non-diabetic volunteers to participate in this 7-week study. If you agree to participate, you will take part in 2 clinic visits that are 4-6 weeks apart. At the clinic visits you will have an oral glucose tolerance test (OGTT) and other blood tests to see how your body processes glucose (sugar). An OGTT is a test in which your drink glucose and then blood samples are taken afterward at specific time points to measure glucose and insulin in your blood. Each clinic visit will last about 5 hours.
Interventions
- PROCEDURE Oral Glucose Tolerance Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-12 |
| Est. Completion | 2032-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06813014
The ClinicalTrials.gov registry entry for NCT06813014 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral Glucose Tolerance Test is the first listed.
NCT06813014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06813014 about?
NCT06813014 is a clinical study titled "Pharmacogenetics of Response to Sitagliptin (PRS)". This is a research study to find out how different people respond to a medication called sitagliptin. Sitagliptin is an FDA approved medication that is used to treat diabetes. We are asking for healthy, non-diabetic volunteers to participate in this 7-week study. If you agree to participate, you wil...
What is the current status of trial NCT06813014?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2026-12. Estimated completion is 2032-12.
What interventions are being tested in trial NCT06813014?
The interventions under investigation include: Oral Glucose Tolerance Test (PROCEDURE).
Who is sponsoring clinical trial NCT06813014?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.